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Objectives This study sought to collect data and evaluate the anecdotal use of transcatheter aortic valve implantation
(TAVI) in pure native aortic valve regurgitation (NAVR) for patients who were deemed surgically inoperable
Background Data and experience with TAVI in the treatment of patients with pure severe NAVR are limited.
Methods Data on baseline patient characteristics, device and procedure parameters, echocardiographic parameters, and
outcomes up to July 2012 were collected retrospectively from 14 centers that have performed TAVI for NAVR.
Results A total of 43 patients underwent TAVI with the CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) at 14 cen-
ters (mean age, 75.3  8.8 years; 53% female; mean logistic EuroSCORE (European System for Cardiac Operative
Risk Evaluation), 26.9  17.9%; and mean Society of Thoracic Surgeons score, 10.2  5.3%). All patients had severe
NAVR on echocardiography without aortic stenosis and 17 patients (39.5%) had the degree of aortic valvular calcifica-
tion documented on CT or echocardiography. Vascular access was transfemoral (n  35), subclavian (n  4), direct
aortic (n  3), and carotid (n  1). Implantation of a TAVI was performed in 42 patients (97.7%), and 8 patients
(18.6%) required a second valve during the index procedure for residual aortic regurgitation. In all patients requiring
second valves, valvular calcification was absent (p  0.014). Post-procedure aortic regurgitation grade I or lower was
present in 34 patients (79.1%). At 30 days, the major stroke incidence was 4.7%, and the all-cause mortality rate was
9.3%. At 12 months, the all-cause mortality rate was 21.4% (6 of 28 patients).
Conclusions This registry analysis demonstrates the feasibility and potential procedure difficulties when using TAVI for severe NAVR. Ac-
ceptable results may be achieved in carefully selected patients who are deemed too high risk for conventional surgery, but
the possibility of requiring 2 valves and leaving residual aortic regurgitation remain important considerations. (J Am Coll
Cardiol 2013;61:1577–84) © 2013 by the American College of Cardiology Foundation
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TAVI for Native Aortic Valve Regurgitation April 16, 2013:1577–84Transcatheter aortic valve im-
plantation (TAVI) has become
the standard of care for extreme
surgical risk patients with symp-
tomatic severe aortic stenosis and
an alternative to open surgery in
those deemed high risk. Since
the first TAVI procedure was
performed in 2002 (1), there has
been a growing worldwide expe-
rience with TAVI, and with this
have come several off-label indica-
tions for this technology. Alternative access routes, bicuspid
valves, valve-in-valve procedures, and TAVI for intermediate-
risk patients are all of increasing interest (2–4).
It is well established that patients with severe aortic
regurgitation and symptoms have a poor prognosis (5,6) and
should be offered surgical aortic valve replacement (7,8).
There are patients with severe aortic regurgitation and at
high or extreme surgical risk for whom conventional surgical
aortic valve replacement may be unsuitable and who might
benefit from transcatheter-based therapy. Until now, there
have been limited experience and no collective published
data on the use of TAVI for pure severe native aortic valve
regurgitation (NAVR) without aortic stenosis.
Methods
Study design. The study was designed as an independent,
worldwide, multicenter voluntary registry of patients treated
with TAVI for pure severe NAVR using the Medtronic
CoreValve (Medtronic, Minneapolis, Minnesota). A total
of 43 patients were collected retrospectively and prospec-
tively from 14 centers worldwide.
Data collection. Registry data were collected from partic-
ipating centers. Data collection was retrospective until
December 2011 and prospective from January through July
2012. Data on baseline patient characteristics, device and
procedure parameters, echocardiographic parameters, and
outcomes up to July 2012 were collected from 14 centers
that have performed TAVI for pure severe NAVR.
Follow-up data regarding adverse events were censored in
July 2012.
Definitions. Pure severe NAVR was defined as severe
ortic regurgitation without aortic stenosis, and aortic ste-
nosis was defined as a peak aortic jet velocity on continuous
wave Doppler of 2.5 m/s (9). Patients with bioprosthetic
xenograft, homograft, or autograft regurgitation were not
included. Aortic valve calcification was assessed on com-
puted tomography (CT) or transesophageal echocardiogra-
phy and defined as grade I (none), grade II (mild), grade III
(moderate), and grade IV (severe), as previously described
(10,11). Procedural success was defined as the successful
transcatheter implantation of a functioning aortic valve
Abbreviations
and Acronyms
CT  computed
tomography
NAVR  native aortic valve
regurgitation
TAVI  transcatheter aortic
valve implantation
VARC  Valve Academic
Research Consortiumaccording to Valve Academic Research Consortium a(VARC) criteria (12). Major clinical and safety endpoints
were also collected and defined according to VARC criteria.
Patient selection. Patients were selected for TAVI by the
heart team at the contributing hospitals. These were real-
world patients deemed unsuitable for surgery due to extreme
risk. For inclusion in this study, patients had to have severe
NAVR without aortic stenosis (i.e., pure, not predominant,
aortic regurgitation). Patients who had undergone any
previous aortic valve surgery were excluded. Examples of
comorbidities that heart teams considered significant
enough to make the risk of surgery unacceptable included
previous radiotherapy, hostile mediastinum, severe left ven-
tricular dysfunction, previous stroke, significant pulmonary
hypertension, and severe pulmonary disease.
Statistical analysis. Categorical variables are expressed as
number and percentage, and continuous variables are ex-
pressed as mean  SD. The Mann-Whitney U test was
used to examine the association between post-procedure
aortic regurgitation and death at 30 days. The chi-square
and Fisher exact tests were used to find significant associa-
tions between aortic valve calcification and need for a second
valve. The Fisher exact test was used to examine the
association between the need for a second valve and mor-
tality at 30 days. Data were analyzed using the SPSS version
17 (SPSS Inc., Chicago, Illinois), and statistical significance
was taken as p  0.05.
Technical aspects. WORKUP. The anatomy in patients
with NAVR is often challenging. These patients often have
a dilated aortic root, a dilated ascending aorta, and often an
elliptical annulus. Figure 1 provides examples from this
study of complex aortic anatomy.
There is good evidence that TAVI patients benefit from
multimodality imaging during pre-procedure planning be-
fore valve sizing and deployment (13–15). In patients
with NAVR, pre-procedure transthoracic echocardiogra-
phy, transesophageal echocardiography, and multislice
3-dimensional CT should be considered mandatory due to
the complex nature of these patients. The annulus should be
carefully examined, and valve sizing should be according to
measurements of the perimeter and area rather than major
and minor orthogonal annular diameters. Where aortic
calcification is absent, a clear understanding of the sur-
rounding anatomy is vital, especially the ascending aortic
diameter and the sinus of Valsalva diameters. When treating
patients with aortic stenosis with the CoreValve (Medtronic),
10% to 20% oversizing with respect to the annulus perim-
eter is recommended when choosing prosthesis size. Al-
though there are no recommendations with respect to device
sizing for TAVI in NAVR, the operators in this study
adhered to the recommendations for aortic stenosis with the
exception of 3 patients in whom oversizing exceeded 20%,
as shown in Figure 2.
ACCESS ROUTES. Although transfemoral access was the
referred route at all centers in suitable anatomy, alternative
ccess routes were dependent on the individual center’s
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April 16, 2013:1577–84 TAVI for Native Aortic Valve Regurgitationexpertise and preference, given the patients’ individual
anatomy. Direct aortic access, subclavian access, and carotid
access were all used as alternatives to transfemoral access
and were previously described alternative access routes for
TAVI (4,16,17).
TAVI for the NAVR procedure. In patients with absent
aortic valve calcification, the procedure can be made more
difficult by the lack of fluoroscopic landmarks to outline the
Figure 1 Examples of Complex Aortic Anatomy
for Transcatheter Aortic Valve Implantation
(A) A dilated aortic root and ascending aorta as a cause of severe aortic regur-
gitation. (B) Extreme angulation of the ascending aorta in a patient who had
valve-sparing ascending aortic surgery for aneurysmal dilation.annulus position and root anatomy. Methods that may assistthe procedure include using fixed landmarks in the thoracic
anatomy such as sternal wires, pacing wires, and vertebral
bodies. Another technique is to use 2 pigtail catheters, as
demonstrated in Figure 3. One is placed in the noncoronary
sinus, and the other is placed in the left sinus. These
techniques can help ensure accurate positioning and reduce
large contrast doses from multiple aortograms.
Figure 2 Device Size Versus Annulus Size
Recommended annulus diameter ranges for CoreValve sizing: 20- to 23-mm
annulus, 26-mm device; 23- to 27-mm annulus, 29-mm device; 26- to 29-mm
annulus, 31-mm device. Note there were 3 patients in whom oversizing above
the recommendations for CoreValve sizing were used (shown in red).
Figure 3 Two-Pigtail Technique
Two pigtails should be placed in the non and left coronary sinuses during
the transcatheter aortic valve implantation procedure. This helps to demon-
strate the aortic annulus where calcification is absent on fluoroscopy. This
2-pigtail technique may also be useful in limiting the amount of contrast
needed for the procedure.
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TAVI for Native Aortic Valve Regurgitation April 16, 2013:1577–84We recommend the use of rapid pacing (heart rate 150 to
180 beats/min) for the deployment of the CoreValve for
severe NAVR. This decreases the regurgitant volume and
systolic blood pressure as well as the risk of prosthesis
movement. We recommend that this be used at least from
one third frame deployment to two thirds frame deployment
(Fig. 4). This improves valve stability and reduces sudden
movements and risk of valve dislocation during the one
Figure 4 Rapid Ventricular Pacing During Deployment
(A) Rapid pacing reduces regurgitant volume and reduces movement of the
prosthesis during deployment. (B) Rapid pacing is recommended during the
one third to two thirds phase of CoreValve deployment in patients with severe
native aortic valve regurgitation.third to two thirds phase.In patients in whom there is significant paravalvular
aortic regurgitation after valve deployment, valvuloplasty is
unlikely to be of benefit and may lead to valve dislocation
toward the aorta. This is due to the fact that unless there is
severely calcified anatomy, the CoreValve is invariably fully
expanded, and the reason for regurgitation is either subop-
timal valve positioning or incorrect initial valve sizing.
Where there is residual significant paravalvular regurgita-
tion, a second valve deployed in a valve-in-valve fashion is
recommended. This should be performed using a snare to
fix the first valve in position (Fig. 5) and prevent ventricular
embolization of the first valve, which is a recognized
complication of valve-in-valve procedures.
Results
Patient demographics. Forty-three patients underwent
TAVI with the Medtronic CoreValve prosthesis in 14 centers
from Europe and Israel up to July 2012. Baseline patient
characteristics are outlined in Table 1. The mean age of the
patients was 75.3  8.8 years, and the majority were female
(53%). The prevalence of severe comorbidities was predictably
high, with a mean logistic EuroSCORE of 26.9 17.9% and
mean Society of Thoracic Surgeons score of 10.2  5.3%.
ach of the 43 patients was deemed unsuitable for surgical
ortic valve replacement by a local heart team on the basis of
evere comorbidities. The causes of NAVR are outlined in
able 2. The majority were due to degenerative changes in the
Figure 5 Snare Technique During Valve-in-Valve
Transcatheter Aortic Valve Implantation
When implanting a second transcatheter aortic valve implantation device, it is
recommended to use a 6-F Amplatz goose neck snare (indicated by arrow, next
to pigtail catheter) to fix the first valve in position while performing a valve-in-
valve procedure. This technique is used to avoid dislocation and embolization
of the first valve into the ventricle.
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aortic regurgitation on echocardiography defined by standard
criteria (18) without aortic stenosis (which was defined as a
peak aortic velocity of 2.5 m/s) and 17 patients (39.5%) had
he degree of aortic valvular calcification documented on CT or
chocardiography (n  12, grade II/mild; n  3, grade
III/moderate; n  1, grade IV/severe) (Table 3). All patients
had pure NAVR; those with mixed valve disease were excluded
from this study.
Procedural results. The procedure results are outlined in
Baseline CharacteristicsTable 1 Baseline Characteristics
Age, yrs 75.3 8.8
Female 23 (53)
Diabetes 9 (20.9)
Previous CABG 12 (27.9)
Creatinine, mol/l 120.9 149.8
GFR, ml/min 44.5 25.3
Chronic renal failure* 9 (20.9)
Previous stroke 9 (20.9)
Hypertension 30 (69.8)
Coronary artery disease 21 (48.8)
Atrial fibrillation 15 (37.2)
Previous myocardial infarction 6 (13.9)
Chronic obstructive pulmonary disease 10 (23.3)
Porcelain aorta 1 (2.3)
NYHA functional class
II 1 (2.3)
III 29 (67.4)
IV 13 (30.2)
Ascending aortic diameter, mm† 35.9 8.8
Sinus of Valsalva dimension, mm† 32.8 4.9
LVEDD, mm 59.4 13.7
LVESD, mm 41.7 14.4
LV ejection fraction, % 45.5 12.9
Aortic regurgitation grade (echocardiography)
II 0
III 24 (55.8)
IV 19 (44.2)
Aortic regurgitation grade (angiography)
II 1 (2.3)
III 22 (51.2)
IV 20 (46.6)
Mitral regurgitation grade
I or lower 29 (67.4)
II 11 (25.6)
IV 3 (7.0)
Pulmonary hypertension‡ 4 (9.3)
Logistic EuroSCORE 26.9 17.9
STS score 10.2 5.3
Values are mean  SD or n (%). *Chronic renal failure was defined as estimated glomerular
ltration rate 30 ml (chronic kidney stage 3 or 4). †Ascending aortic and sinus of Valsalva
imensions were obtained either by computed tomography or transesophageal echocardiography,
nd ascending aortic dimensions in the 4 patients with aortic aneurysm were 65, 53, 41, and 45
m respectively. ‡Pulmonary hypertension was defined as systolic pulmonary artery pressure60
mm Hg.
CABG  coronary artery bypass graft; EuroSCORE  European system for cardiac operative risk
valuation; GFR  glomerular filtration rate; LV  left ventricular; LVEDD  left ventricular
end-diastolic dimension; LVESD left ventricular end-systolic dimension; NYHA New York Heart
Association; STS  Society of Thoracic Surgeons.Table 4. All patients had either pre- or intraproceduretransesophageal echocardiography to assess annulus size.
Pre-TAVI CT was performed in 19 patients (44.2%).
Transfemoral access was used in the majority of patients
(n  35), with 4 patients treated via the subclavian ap-
proach, 3 via the direct aortic approach, and 1 via the
carotid. The choice of carotid access was at the operator’s
discretion if other access routes were less favorable due to
complex anatomy. The technique used by the operators in
this alternative-access carotid case was previously de-
scribed (16).
Annulus size was calculated by CT (in those who had
pre-procedure CT) or transesophageal echocardiography.
The mean annulus size was 24  2.3 mm, and a 29-mm
prosthesis was most commonly used (29-mm annulus in 22
patients, 26-mm annulus in 14 patients, and 31-mm annu-
lus in 7 patients). Figure 2 shows the relationship between
annulus size and the device size chosen for the TAVI
procedure. There were 3 patients in whom oversizing of the
device exceeded the 20% oversizing according to standard
recommendations for valve sizing with respect to annulus
diameter. These decisions were made at the operators’
discretion when there were perceived concerns regarding
paraprosthetic regurgitation or valve migration.
Implantation of a TAVI prosthesis was performed in 42
of 43 patients (97.7%), with 8 patients (18.6%) requiring a
second valve during the index procedure for residual aortic
regurgitation. In all patients in whom a second valve was
needed, aortic valve calcification was absent (p  0.014)
Fig. 6). Aortic regurgitation of grade I or lower was present
ost-procedurally in 34 patients (79.1%) (grade II in 7
atients and grade III in 2 patients). Of the 8 patients who
equired a second valve, 5 had grade II and 1 had grade III
ortic regurgitation post-procedure. The remaining 2 pa-
ients who required second valves had grade I aortic regur-
itation post-procedure. There was no post-procedure grade
V aortic regurgitation and no procedure mortality; how-
ver, 1 patient required conversion to open surgery and
Mechanism of Aortic RegurgitationTable 2 Mechanism of Aortic Regurgitation
Degenerative 27 (62.8)
Post-endocarditis 6 (14.0)
Aortic aneurysm 4 (9.3)
Aortic valve cusp restriction due to rheumatoid vasculitis,
Takayasu’s arteritis, unknown
3 (7.0)
Post-radiotherapy 2 (4.7)
Chronic dissection 1 (2.3)
Values are n (%).
Aortic Valve CalcificationTable 3 Aortic Valve Calcification
I (none) 26 (60.5)
II (mild) 13 (30.2)
III (moderate) 3 (7.0)
IV (severe) 1 (2.3)Values are n (%).
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TAVI for Native Aortic Valve Regurgitation April 16, 2013:1577–84aortic valve replacement due to residual severe aortic regur-
gitation post-deployment. Modified RIFLE criteria stage 3
acute kidney injury occurred in 2 patients (4.7%), 1 of whom
required long-term renal replacement therapy.
The VARC-defined procedure success for TAVI was
74.4% when grade II or higher residual aortic regurgitation
and the need for a second valve were taken into account.
Clinical outcomes. The safety endpoints and clinical out-
omes according to the VARC definitions are summarized
n Table 5. The 30-day all-cause mortality rate was 9.3%
n 4) with a cardiovascular mortality rate of 2.3% (n 1).
Major stroke defined according to VARC occurred in 2
patients (4.7%) at 30 days. New conduction abnormalities
requiring permanent pacing were present in 5 patients
(16.3%). There were major access-related vascular compli-
Procedural ResultsTable 4 Procedural Results
Access
Transfemoral 35 (81.4)
Subclavian 4 (9.3)
Direct aortic 3 (7.0)
Carotid 1 (2.3)
Implantation of prosthesis 42 (97.7)
Annulus size, mm 24.0 2.3
Prosthesis size, mm
29 22 (51.2)
26 14 (32.6)
31 7 (16.3)
Valve post-dilation 4 (9.3)
Second valve required 8 (18.6)
Post-procedure AR grade
I or lower 34 (79.1)
II 7 (16.3)
III 2 (4.7)
New permanent pacemaker 7 (16.3)
Values are n (%) or mean  SD.
AR  aortic regurgitation.
Figure 6 Relationship Between Aortic Valve
Calcification and Need for a Second Valve
Eight of 26 patients (31%) without aortic valve calcification required a second
valve, whereas none of the 17 patients with calcification (grades II, III, and IV)
required second valves to achieve an acceptable result (p  0.014). This asso-
ciation was statistically significant in chi-square and 2-sided Fisher exact tests.cations in 3 patients (7%), and there were no myocardial
infarctions according to the VARC definition. The mean
left ventricular ejection fraction improved from 45.5  12%
to 49.6  14.2% at 30 days (p  0.02). The functional class
f the patients at baseline and 30 days is outlined in
igure 7. The 12-month all-cause mortality rate was 21.4%
6 of 28 patients), and the cardiovascular mortality rate was
0.7% (n  3). The need for second valve did not predict
mortality at 30 days (p  0.18), and there was no statisti-
Clinical and Safety Outcomes According to VARC*Table 5 Clinical and Safety Outcomes According to VARC*
Mortality
30-day all-cause 4 (9.3%)
30-day cardiovascular 1 (2.3%)
12 month all-cause 6/28 (21.4)
12-month cardiovascular 3/28 (10.7)
Major stroke (30 days) 2 (4.7)
Major bleeding 8 (18.6)
Acute kidney injury (stage 3) 2 (4.7)
Myocardial infarction 0
Access site complications 6 (14.0)
Major 3 (7.0)
Minor 3 (7.0)
VARC procedure success 32 (74.4)
Values are n (%). *The previously outlined VARC definitions of stroke (minor, modified Rankin Sale
score 2; major, modified Rankin Scale score 2), major bleeding, acute kidney injury (modified
RIFLE criteria stage 3), myocardial infarction, major andminor access site complications were used
in this analysis.
VARC  Valve Academic Research Consortium.
Figure 7 NYHA Functional Status
This figure shows the proportion of patients in each New York Heart Associa-
tion (NYHA) functional class on the basis of their symptoms at baseline and at
30 days. Note that the majority of patients were in NYHA functional class I or II
at 30 days post-procedure.
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post-procedure aortic regurgitation (p  0.13, z  1.55).
Causes of 12-month mortality included perforated gastric
ulcer, fatal bleeding after chest tube insertion, progressive
cardiac failure and cardiogenic shock, pneumonia, arrhyth-
mia, and a further unwitnessed death due to presumed
arrhythmia. Of the 4 patients who had aortic regurgitation
due to aortic aneurysm/aneurysmal dilation, 3 of them had
died at 6 months (arrhythmia, cardiac failure, and perfo-
rated gastric ulcer).
Discussion
TAVI has now become the standard of care for patients with
symptomatic severe aortic stenosis who are considered at
extreme risk for surgery and an acceptable alternative to surgery
for those at high risk (19,20). Many patients with mixed aortic
valve disease with severe aortic stenosis and at least moderate
aortic regurgitation have been successfully treated with both
balloon-expandable and self-expanding TAVI (3,21), but se-
vere NAVR without aortic stenosis is still considered a con-
traindication to TAVI (22). Furthermore, we were aware that
this therapy had been used anecdotally in small numbers of
patients in individual centers (23–25). We thought that it was
important to collect these data in a registry, which have not, to
our knowledge, been reported before.
There are several reasons to explain why TAVI has not
been used in large numbers of patients with NAVR. First,
population surveys suggest that aortic stenosis is far
more prevalent than aortic regurgitation (33.9% vs. 10.4% of
patients with single left-sided valvular heart disease), and
patients are 4 times more likely to have surgical AVR for
aortic stenosis than aortic regurgitation (7,26). Second,
although aortic stenosis is predominantly caused by degen-
eration and calcification of the valve, NAVR is the conse-
quence of diverse etiologies, affecting a younger age group
with patients who are very likely to be surgical candidates.
Clearly surgery is, and will remain, the gold standard
treatment for the overwhelming majority of patients with
pure NAVR. Furthermore, involvement of the ascending
aorta is present in a proportion of patients, which mandates
open surgical treatment (7,8). Finally, patients with aortic
regurgitation have a more complex and variable anatomy,
making transcatheter therapies more challenging.
The results of this study need to be considered with caution.
Implantation of a transcatheter valve was undertaken in 42 of
43 patients. Although this is encouraging and demonstrates
feasibility, 8 patients required 2 transcatheter valves, and 9
patients had residual aortic regurgitation that was more than
mild. One patient required conversion to open surgery. Thus,
VARC-defined success was 74.4%. There was no statistically
significant association between the degree of aortic regurgita-
tion post-procedure or need for a second valve and death, but
this is likely due to low study numbers.
The issue of residual aortic regurgitation is important. All
studies examining the effect of post-TAVI aortic regurgita-tion have shown that leaving more than grade II aortic
regurgitation is associated with worse outcomes, and this is
clearly an important factor in younger cohorts of patients.
Stroke rates, vascular complications, bleeding, and mortality
compare favorably with published trials and registries for
TAVI in the treatment of aortic stenosis, but one would expect
this to be so, as patients with pure aortic regurgitation are
younger with fewer comorbidities (19,20,26–30). Thus, al-
though these results are encouraging for those patients who are
truly ineligible for surgery, surgical valve replacement remains
the gold standard for those who can undergo it, even at high
risk. Furthermore, there is an increasing number of patients in
whom the native aortic valve can be preserved during surgery.
This study has shown a high incidence of the need for a
second valve compared with other studies using the same
device in the treatment of aortic stenosis (30). Although the
need for a second valve is likely to be multifactorial, there
was a strong correlation with absent valvular calcification.
Absent aortic valve calcification may lead to reduced fixation
of the lower part of the valve frame at the annulus during
deployment, resulting in malpositioning. This may be fur-
ther exacerbated by increased movement of the valve pros-
thesis in the regurgitant jet. Dilation of the aortic root and
ascending aorta, which is common in NAVR, may also
contribute. This problem may be overcome by valve designs
that are fully retrievable and repositionable, and valvular
fixation may be improved, even in the absence of calcium
with new anatomically oriented valve designs (31,32).
It was apparent, despite small numbers, that patients with
an aneurysm of the ascending aorta in this study had a poor
response to treatment with TAVI (3 of 4 patients died
within 6 months of treatment). This suggests that TAVI is
unlikely to alter the prognosis of these patients and that
aneurysmal dilation should be considered a contraindication
to TAVI in patients with NAVR.
In this study, the operators adhered to valve sizing
recommendations with the exception of 3 patients in whom
oversizing of the prosthesis exceeded 20% with respect to
the native annulus dimension. Although oversizing may be
advantageous in NAVR without calcification to prevent
dislocation and paravalvular regurgitation, this study was
too small to make conclusions or recommendations with
respect to valve sizing in these patients. Despite this, when
the annulus measurement is on the borderline between 2
valve sizing recommendations, the authors would suggest
using the larger of the 2 potential prosthesis choices.
Study limitations. This was a small, predominantly retro-
spective voluntary registry of a novel indication for transcath-
eter valve therapy, and we are cautious to draw firm conclusions
from these data. There are likely to have been many more
patients with severe NAVR who were considered for TAVI
but were turned down on the basis of anatomy, difficulties in
funding, or reservations on the part of the treating cardiologist,
and this should be kept in perspective when considering the use
of TAVI for NAVR. We recognize that the assessment of
residual aortic regurgitation after TAVI is operator and labo-
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laboratory, which would be advantageous in future studies.
Conclusions
This study demonstrates the feasibility and potential pro-
cedure difficulties of treating patients with pure severe
NAVR without aortic stenosis who have been deemed
unsuitable for surgery with TAVI using the Medtronic
CoreValve. Despite the variations in causes of valvular regur-
itation and complexity of patient anatomy, acceptable results
n this high-risk group of patients can be achieved. The
ossibilities of requiring 2 valves and leaving significant resid-
al aortic regurgitation remain important considerations.
Reprint requests and correspondence: Dr. David Alexander Roy,
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